A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

NCT05873686 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
NSCLC (Non-small Cell Lung Cancer)
Renal Cancer
Mesothelioma
Non-Small Cell Squamous Lung Cancer
Non-small Cell Lung Adenocarcinoma

Interventions

DRUG: NXP900

Sponsor

Nuvectis Pharma, Inc.